MQS Management LLC Buys Shares of 3,708 Edwards Lifesciences Co. (NYSE:EW)

MQS Management LLC bought a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 3,708 shares of the medical research company’s stock, valued at approximately $245,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Park Avenue Securities LLC raised its position in shares of Edwards Lifesciences by 0.5% in the 2nd quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company’s stock worth $2,169,000 after acquiring an additional 108 shares in the last quarter. City State Bank increased its position in Edwards Lifesciences by 16.5% during the 2nd quarter. City State Bank now owns 917 shares of the medical research company’s stock valued at $85,000 after buying an additional 130 shares in the last quarter. Stableford Capital II LLC increased its position in Edwards Lifesciences by 2.7% during the 2nd quarter. Stableford Capital II LLC now owns 6,104 shares of the medical research company’s stock valued at $533,000 after buying an additional 159 shares in the last quarter. Purus Wealth Management LLC increased its position in Edwards Lifesciences by 5.2% during the 2nd quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company’s stock valued at $297,000 after buying an additional 160 shares in the last quarter. Finally, Busey Bank increased its position in Edwards Lifesciences by 1.9% during the 2nd quarter. Busey Bank now owns 8,838 shares of the medical research company’s stock valued at $816,000 after buying an additional 165 shares in the last quarter. 79.46% of the stock is owned by institutional investors.

Insider Activity at Edwards Lifesciences

In related news, insider Larry L. Wood sold 25,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares in the company, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Daveen Chopra sold 1,250 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The trade was a 4.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 41,250 shares of company stock valued at $2,744,438. 1.29% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on EW shares. Bank of America lowered Edwards Lifesciences from a “buy” rating to a “neutral” rating and reduced their target price for the company from $105.00 to $75.00 in a research report on Thursday, July 25th. Jefferies Financial Group downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their price target for the company from $85.00 to $70.00 in a research note on Wednesday, September 18th. Baird R W downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 25th. The Goldman Sachs Group lowered their target price on Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating on the stock in a research note on Friday, July 26th. Finally, Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Seventeen research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $75.67.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $67.76 on Friday. The business has a 50 day simple moving average of $67.42 and a two-hundred day simple moving average of $76.37. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The stock has a market capitalization of $39.96 billion, a P/E ratio of 9.78, a PEG ratio of 3.74 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter in the prior year, the firm earned $0.59 earnings per share. The business’s revenue was up 8.9% compared to the same quarter last year. As a group, analysts predict that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.